LENSAR Q3 2026 earnings

LNSR · 2026-11-10 07:10 BMO ET · 8-K on SEC

Revenue declined 1% YoY, but recurring revenue grew 17% YoY and now represents 89% of total revenue.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$14.1M-1.0%—Ex. 99.1, income statement
EPS (GAAP)-$0.38N/M—Ex. 99.1, income statement
EPS (adjusted)N/MN/M—Ex. 99.1, income statement
Net income-$4.7MN/M—Ex. 99.1, income statement
Adj. EBITDA$1.7MN/M—Ex. 99.1, income statement
Adj. EBITDA margin12.0%+12.0 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Product$10.7M-5.7%76%System sales declined sequentially and vs prior year
Lease$1.7M9.7%12%—
Service$1.7M22.7%12%—

Margins and costs

  • Gross margin 57.8% (prior 42.2%, change +15.6 pp)
  • Operating expenses $9.6M (+29.5% YoY)
  • One-offs in the quarter Change in fair value of warrant liabilities: -$3.4M; Acquisition-related income: $10.0M
  • Effective tax rate N/M
  • Non-GAAP bridge Adds back stock-based compensation, change in fair value of warrant liabilities, acquisition-related income and costs, and strategic transaction-related costs

KPIs

MetricActualPrior quarterPrior yearChange
Procedure volume52,54558,68246,811+12.0%
Total Laser Installed Base450445425+6.0%
Total ALLY Installed Base225215185+22.0%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Total revenue declined 1% YoY due to lower system sales; procedure revenue grew 17% YoY; recurring revenue grew 17% YoY to $12.6M.
  • EPS story Net loss widened to -$4.7M, driven by a $3.4M non-cash warrant liability loss and higher operating expenses.
  • One-off check Change in fair value of warrant liabilities: -$3.4M (non-cash)

The good

  • Recurring revenue grew 17% YoY to $12.6M
  • Procedure volume grew 12% YoY to 52,545
  • Adjusted EBITDA turned positive to $1.7M
  • Total ALLY installed base grew 22% YoY to 225 systems

The bad

  • Total revenue declined 1% YoY to $14.1M
  • Product revenue declined 5.7% YoY to $10.7M
  • Operating loss of $1.4M

The ugly

  • none

Open questions

  • What is the specific impact of the $10.0M acquisition-related income on future operations?
  • How will the company sustain profitability given the current operating loss and cash burn?
  • What are the specific strategic transaction-related costs mentioned in the non-GAAP bridge?
Full release

LENSAR (LNSR) earnings release, November 10, 2026

LENSAR, Inc. (LNSR) · Form 8-K, Item 2.02 · Filed · SEC filing

LENSAR®

Reports Third Quarter 2026 Financial Results and Provides Business Update

10 ALLY Robotic Cataract Laser Systems®

(“ALLY System”) Placements in Third Quarter 2026; Backlog of 12 ALLY Systems as of September 30, 2026

Third Quarter Recurring Revenue Grew 17% Year Over Year to $12.6 Million

Total Laser Installed Base Reaches 450 Systems; ALLY System Installed Base Expands 22% Year Over Year

ORLANDO, Fla. (Nov 10, 2026)

- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2026 and provided an update on key operational initiatives.

“In-line with the expectations we shared in August, our third quarter results reflected the typical summer seasonality during which surgical scheduling and purchasing decisions contribute to a more measured pace of activity, leading to a sequential decline from a very strong second quarter,” said Nick Curtis, President and CEO of LENSAR. “Total revenue declined 1% year-over-year due to lower system sales against a robust number of sold systems in the prior year period, which was partially offset by growth in both procedure volume and recurring revenue. We see the year-over-year growth in these two revenue indicators as clear evidence of the increasing strength of our operational foundation, which we plan to continue leveraging to drive sustainable growth over the long-term.”

“LENSAR was built on innovation, and that remains a fundamental aspect of how we intend to continue competing and gain further ground in the laser cataract surgery market,” continued Curtis. “Over the quarter, our ALLY installed base grew to approximately 225 systems, expanding our opportunity to support surgeons and generate recurring revenue through continued growth in procedure volumes. We remain focused on advancing the capabilities and adoption of our technology, deepening relationships with surgeon partners and distributors, and utilizing this growing installed base to drive success. While quarterly results may fluctuate due to the timing of system sales and placements, among other factors, our commitment to innovation and disciplined commercial execution remains unchanged.”

LENSAR Q3 2026 Financial Summary

*N/M = Not meaningful

Third Quarter 2026 Financial Results

During the three months ended September 30, 2026, total revenue was $14.1 million, compared with $14.3 million in the prior year period. As disclosed in the Company’s second quarter operational update, the third quarter is typically the slowest of the year for cataract procedures and sales activity given extended holidays in various parts of the world and summer vacations in the United States. Procedure volume was 52,545 in the third quarter, compared with 46,811 in the third quarter of 2025. Recurring revenue increased 17% year over year to $12.6 million and represented 89% of total revenue, compared with $10.8 million, or 75% of total revenue a year earlier.

The Company placed 10 ALLY Systems during the third quarter, bringing the total installed ALLY base to approximately 225 ALLY Systems at quarter end. The total installed base reached approximately 450 systems. As of September 30, 2026, the Company had a backlog of 12 ALLY Systems pending installation. The Company continues to prioritize differentiated technology and broader adoption of the ALLY System as it works to strengthen its recurring revenue base over time.

The following table provides information about revenue and recurring revenue, which we consider to be all components of our revenue except for the sales of our systems:

The following table provides information about procedure volume:

Cash, cash equivalents, and investments totaled $12.6 million as of September 30, 2026, compared to $18.0 million at December 31, 2025.

Conference Call

LENSAR management will host a conference call and live webcast to discuss the results and provide an update on the Company today, November 10, 2026, at 8:30 a.m. ET.

To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. The call and webcast replay will be available for 30 days.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System® as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.

Financial statements

Income Statement

LENSAR Q3 2026 Financial Summary

Q3 2026Q3 2025% Change
Revenue$14.1M$14.3M-1.0%
Recurring revenue$12.6M$10.8M17.0%
Procedure revenue$9.2M$7.8M17.0%
Procedure volume52,54546,81112.0%
Recurring revenue %89.0%75.0%+14 pts
Total Laser Installed Base4504256.0%
Total ALLY Installed Base22518522.0%
Net Loss$(4.7)M$(3.7)MN/M
Adjusted EBITDA$1.7M$(0.3)MN/M

Income Statement

Three Months Ended September 30, (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
System1,5473,5465,1928,754
Recurring revenue:
Procedure9,1687,82128,64124,441
Lease1,7121,5605,1655,089
Service1,7041,3895,0564,126
Total recurring revenue12,58410,77038,86233,656
Total revenue14,13114,31644,05442,410
Recurring revenue %89.0%7588.0%79

Income Statement

Three Months Ended September 30, — (In thousands, except per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue
Product10,71511,36733,83333,195
Lease1,7121,5605,1655,089
Service1,7041,3895,0564,126
Total revenue14,13114,31644,05442,410
Cost of revenue (exclusive of amortization)
Product3,4945,64911,28014,430
Lease8369092,5762,598
Service1,6371,7225,8765,197
Total cost of revenue5,9678,28019,73222,225
Operating expenses
Selling, general and administrative expenses8,06312,02016,73334,827
Research and development expenses1,3071,3673,9654,326
Amortization of intangible assets227229684691
Total operating expenses9,59713,61621,38239,844
Operating (loss) income-1,433-7,5802,940-19,659
Other (expense) income
Change in fair value of warrant liabilities-3,3653,73421,813-13,648
Acquisition-related income10,000
Other income, net75133391485
Net (loss) income-4,723-3,71335,144-32,822
Other comprehensive (loss) income
Change in unrealized gain (loss) on investments8-4-1
Net (loss) income and comprehensive (loss) income-4,723-3,70535,140-32,823
(Loss) income per common share:
Basic-0.38-0.311.43-2.75
Diluted-0.38-0.310.56-2.75
Weighted-average number of common shares used in calculation of net (loss) income per common share:
Basic12,39812,04412,28611,920
Diluted12,39812,04423,86811,920

Balance Sheet

September 30, 2026 — BALANCE SHEETS (In thousands, except per share amounts)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents12,62212,974
Short-term investments5,004
Accounts receivable, net of allowance of $68 and $62, respectively5,1386,377
Notes receivable, net of allowance of $10 and $6, respectively485295
Inventories25,14121,520
Prepaid and other current assets1,101601
Total current assets44,48746,771
Property and equipment, net524505
Equipment under lease, net14,43415,485
Notes and other receivables, long-term, net of allowance of $10 and $15, respectively510731
Intangible assets, net4,5075,191
Other assets2,6062,747
Total assets67,06871,430
Current liabilities:
Accounts payable9,85518,982
Accrued liabilities6,4457,771
Deferred revenue2,7123,074
Operating lease liabilities799747
Acquisition-related deposit10,000
Total current liabilities19,81140,574
Long-term accounts payable1,875
Long-term operating lease liabilities1,3871,988
Warrant liabilities18,38140,194
Other long-term liabilities763909
Total liabilities42,21783,665
Series A Redeemable Convertible Preferred Stock, par value $0.01 per share, 20 shares authorized at September 30, 2026 and December 31, 2025; 20 shares issued and outstanding at September 30, 2026 and December 31, 2025; aggregate liquidation preference of $20,000 at September 30, 2026 and December 31, 202513,78413,784
Stockholders’ equity (deficit):
Common stock, par value $0.01 per share, 150,000 shares authorized at September 30, 2026 and December 31, 2025; 12,291 and 11,993 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively123120
Additional paid-in capital153,375151,432
Accumulated other comprehensive income4
Accumulated deficit-142,431-177,575

Forward-looking Statements... (truncated)atements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: any anticipated effects of the termination of the agreement governing the merger on the value of our common stock; the outcome of any legal proceedings that may be instituted against us and others relating to the merger; our history of operating losses and ability to achieve or sustain profitability; our ability to develop, receive and maintain regulatory clearance or certification of and successfully commercialize the ALLY System and to maintain our LENSAR Laser System; the impact to our business, financial condition, results of operations and our suppliers and distributors as a result of global macroeconomic conditions; the willingness of patients to pay the price difference for our products compared to a standard cataract procedure covered by Medicare or other insurance; our ability to grow our U.S. sales and marketing organization or maintain or grow an effective network of international distributors; our future capital needs and our ability to raise additional funds on acceptable terms, or at all; the impact to our business, financial condition and results of operations as a result of a material disruption to the supply or manufacture of our systems or necessary component parts for such system or material inflationary pressures or enacted tariffs affecting pricing of component parts; our ability to compete against competitors that have longer operating histories, more established products and greater resources than we do; our ability to address the numerous risks associated with marketing, selling and leasing our products in markets outside the United States; the impact to our business, financial condition and results of operations as a result of exposure to the credit risk of our customers; our ability to accurately forecast customer demand and manage our inventory levels; the impact to our business, financial condition and results of operations if we are unable to secure adequate coverage or reimbursement by government or other third-party payors for procedures using our ALLY System or our other products, or changes in such coverage or reimbursement; the impact to our business, financial condition and results of operations of product liability suits brought against us; risks related to government regulation applicable to our products and operations; and risks related to our intellectual property and other intellectual property matters. In addition, a number of other important factors could cause the Company’s actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, to be filed with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com.

All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures:

The Company prepares and analyzes operating and financial data and non-GAAP measures to assess the performance of its business, make strategic and offering decisions and build its financial projections. The key non-GAAP measures it uses are EBITDA and Adjusted EBITDA. EBITDA is defined as net (loss) income before interest expense, interest income, income tax expense, depreciation and amortization expenses. EBITDA is a non-GAAP financial measure. EBITDA is included in this filing because we believe that EBITDA provides meaningful supplemental information for investors regarding the performance of our business and facilitates a meaningful evaluation of actual results on a comparable basis with historical results. Adjusted EBITDA is also a non-GAAP financial measure. We believe Adjusted EBITDA, which is defined as EBITDA and further excluding stock-based compensation expense, change in fair value of warrant liabilities, acquisition-related income and costs, and strategic transaction-related costs provides meaningful supplemental information for investors when evaluating our results and comparing us to peer companies as stock-based compensation expense and change in fair value of warrant liabilities are significant non-cash charges, and acquisition-related income and costs and strategic transaction-related costs are not part of our core operating performance. We use these non-GAAP financial measures in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and, therefore, any non-GAAP measures we use may not be directly comparable to similarly titled measures of other companies. Investors should not consider our non-GAAP financial measures in isolation or as a substitute for an analysis of our results as reported under GAAP.

Reconciliations of EBITDA and Adjusted EBITDA to their most comparable GAAP financial measure are set forth below.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · LENSAR earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.